Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina

Lucero, Luciana González; Barbaglia, A. L.; Bellomio, Verónica; Bertolaccini, M. C.; Escobar, Mariana; Sueldo, H. R.; Yacuzzi, Maria S; Carrizo, Gabriel; Robles, Norma; Rengel, Silvia; Cristofari, A.; Leal, M; Vasquez, Doralia L; Quinteros, Ana; Seleme, Gladys; Molina, María J.; Pera, O.; Dip, Rodolfo; Olea, Ana C; Torres, Alberto Y; Echazu, Mariana Espindola; Arquez, Gustavo; Lazaro, Hector; Colombres, Francisco; Juarez, Laura; Romano, Olga; Paz, Silvia; Santana, Mirta; Galindo, L. M.; Lucero, Eleonora

doi:10.1177/0961203320957719

Cited by 9 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five and ten-year survival differed in incident cohorts with patient inclusion before and after 1990 (five-year survival 80% versus 92% and ten-year survival 63% versus 88%) [10,[12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. For all studies with patient inclusion starting after 1990, the five-year survival was 90% or more, except for Barbados and Wisconsin [9,11,14,20,23,27,29]. In studies on total SLE cohorts, the SMR ranges from 1.9 to 4.6 [9,19,20,26,27,[30][31][32].…”

Section: Standardized Mortality Rate and Survivalmentioning

confidence: 99%

Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts

Moe

Haukeland

Molberg

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Accurate knowledge of outcomes in Systemic Lupus Erythematosus (SLE) is crucial to understanding the true burden of the disease. The main objective of this systematic review was to gather all population-based studies on mortality, end-stage renal disease (ESRD) and cancer in SLE. Method: We performed a systematic literature search in two electronic databases (MEDLINE and Embase) to identify all population-based articles on SLE and survival, mortality, ESRD and cancer. The SLE diagnosis had to be verified. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA). Results: We included 40/1041 articles on mortality (27), ESRD (11) and cancer (3), of which six were defined as inception studies. In the total SLE cohort, the standardized mortality ratio ranged from 1.9 to 4.6. Cardiovascular disease was the most frequent cause of death in studies with follow-up times over 15 years. SLE progressed to ESRD in 5–11% of all SLE patients. There are no data supporting increased cancer incidence from population-based inception cohorts. Conclusion: There is a need for more population-based studies on outcomes of SLE, especially inception studies, with the use of control groups and follow-up times over 15 years.

show abstract

Section: Standardized Mortality Rate and Survivalmentioning

confidence: 99%

Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts

Moe

Haukeland

Molberg

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…The prevalence was 58.6 of cases per 100,000 inhabitants in the city of Buenos Aires and 24.3 per 100,000 inhabitants in Tucumán. 1,2…”

Section: Introductionmentioning

confidence: 99%

Multicenter lupus register from Argentina, the RELESSAR database: Influence of ethnicity on disease phenotype

García

Alba

Campo-Pérez

et al. 2022

Lupus

Self Cite

View full text Add to dashboard Cite

Objective The objective is to describe the main characteristics of patients with systemic lupus erythematosus (SLE) in Argentina and to examine the influence of ethnicity on the expression of the disease. Patients and methods RELESSAR is a multicentre register carried out by 106 researchers from 67 rheumatologic Argentine centres. It is a cross-sectional study of SLE (1982/1997 ACR) patients. RELESSAR electronic database includes demographic, cumulative SLE manifestations, SELENA-SLEDAI, SLICC-SDI, Katz’s severity and Charlson’s comorbidity indexes and treatment patterns. Results We included 1,610 patients, 91.7% were female with a median age at diagnosis of 28.1 ± 12.8; 96.2% met ≥4 ACR 1982/97 criteria. Frequent manifestations were arthritis (83.5%), malar rash (79.5%), photosensitivity (75.3%), haematological (63.8%) and renal disease (47.4%), antinuclear antibodies (96%), anti-dsDNA (66.5%) and anti-Smith antibodies (29%). The mean Selena-SLEDAI score at last visit was 3.18 (SD 4.3) and mean SDI was 1 (SD 1.3). The accumulated treatments most frequently used were antimalarials (90.4%), corticosteroids (90%), azathioprine (31.8%), intravenous cyclophosphamide (30.2%), mycophenolate mofetil or mycophenolic acid (24.5%), methotrexate (19.3%), belimumab 5.3% and rituximab 5.1%. Refractory lupus was diagnosed in 9.3% of the cases. The main causes of death were lupus activity (25.0%), activity and concomitant infections (25.0%), infections (18.2%), vascular disease (13.6%) and cancer (4.5%). Mortality was associated with higher SLEDAI, Katz, damage indexes and comorbidities. Of the 1610 patients included, 44.6% were Caucasian, 44.5% Mestizo, 8.1% Amerindian and 1.2% Afro-Latin American. Mestizo patients had higher male representation, low socioeconomic status, more inadequate medical coverage, fewer formal years of education and shorter disease duration. Polyadenopathies and Raynaud’s phenomenon were more frequent in Caucasians. In the logistic regression analysis higher damage index (OR 1.28, CI 95% 1.02–1.61, p = 0.03) remained associated to mestizo ethnicity. Conclusions This study represents the largest number of adult patients with SLE studied in Argentina. Caucasian patients were differentiated by having Raynaud’s phenomenon and polyadenopathy more frequently, while patients of Mestizo origin had higher damage indexes.

show abstract

“…On the other hand, Cortes Verdu et al described in their recent 2020 report that SLE prevalence was of 210 cases per 100 000 inhabitants (95% CI: 110‐400) in Spain. This was one of the highest reported prevalences in most international epidemiological studies 28 …”

Section: Discussionmentioning

confidence: 68%

A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman Lupus Study

et al. 2021

View full text Add to dashboard Cite

Aim This study is a longitudinal multicenter study which aims to find the prevalence, the demographic data, survival and mortality rates of patients with systemic lupus erythematosus (SLE) in Oman. Method All Omani patients, pediatrics and adults diagnosed with SLE, who fulfill either the 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics classifications criteria for SLE were included from January 2006 till February 2020. Results In total 1160 patients were included in this cohort. Data analysis showed that patient’s ages ranged from 2‐82 years with female predominance and female‐to‐male ratio of 7:1 (87.7% female,12.3% male). The mean prevalence of SLE among different age groups was 38.8 (range 5‐63 per 100 000 inhabitants). The mortality rate was found to be 5%. Male patients had significantly higher mortality rate than females (7.6% vs 5.4%, P value = .04). Sepsis was the commonest cause of mortality (34%). The coexistence of systemic sclerosis correlates significantly with death (P = .002). Survival analysis in our data showed 5, 10, 20, 40‐year survival rates of 100%, 100%, 99% and 90% respectively for antinuclear antibody (ANA) positive patients and lower survival rate for ANA negative patients with 5,10, 20, 40‐year survival rates of 100, 99%, 99% and 75%, respectively. Conclusion This study showed that the mean prevalence of SLE in Oman to be 38.8 (range 5‐63) per 100 000 inhabitants. The 40‐year survival rate among patients with positive ANA was found to be 90%, while patients with negative ANA had worse survival outcomes.

show abstract

Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina

Cited by 9 publications

References 24 publications

Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts

Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts

Multicenter lupus register from Argentina, the RELESSAR database: Influence of ethnicity on disease phenotype

A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman Lupus Study

Contact Info

Product

Resources

About